CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-24 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −15,000 | $42.00 | $630K | 88,787 |
| 2025-12-24 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −15,000 | 76,000 | ||
| 2025-12-24 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −7,402 | $40.00 | $296K | 38,233 |
| 2025-12-24 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −4,980 | $40.00 | $199K | 113,013 |
| 2025-12-24 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +60,000 | $20.61 | $1.2M | 161,443 |
| 2025-12-24 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −60,000 | $40.10 | $2.4M | 101,443 |
| 2025-12-24 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −60,000 | 0 | ||
| 2025-12-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −2,910 | $36.00 | $105K | 45,635 |
| 2025-12-01 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +20,000 | $16.23 | $325K | 112,083 |
| 2025-12-01 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −20,000 | $35.01 | $700K | 92,083 |
| 2025-12-01 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −20,000 | 0 | ||
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +10,000 | $25.25 | $253K | 64,410 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +17,500 | $26.88 | $470K | 81,910 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +15,000 | $27.50 | $413K | 96,910 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +12,500 | $22.40 | $280K | 109,410 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +6,250 | $8.93 | $56K | 115,660 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −67,115 | $36.00 | $2.4M | 48,545 |
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −17,500 | 0 | ||
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −15,000 | 2,500 |
Page 15 of 51 · 1,020 trades